MODULATION OF PD-L1 EXPRESSION IN PROSTATE CANCER CELLS THROUGH ANDROGEN RECEPTOR INHIBITION DIFFERS DEPENDING ON RECEPTOR STATUS.

N Najafzade, E Ozgur, S B Gazioglu, E E Yoruker, U Gezer
{"title":"MODULATION OF PD-L1 EXPRESSION IN PROSTATE CANCER CELLS THROUGH ANDROGEN RECEPTOR INHIBITION DIFFERS DEPENDING ON RECEPTOR STATUS.","authors":"N Najafzade, E Ozgur, S B Gazioglu, E E Yoruker, U Gezer","doi":"10.15407/exp-oncology.2025.01.060","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint blockade (ICB) therapy targeting the PD-1/PD-L1 axis results in poor outcomes in prostate cancer (PCa). PD-L1, the most commonly used predictive marker for the efficacy of PD-1/PD-L1-targeted immunotherapy, appears to be rarely or at low levels expressed in primary androgen-responsive PCa tumors, with higher levels in advanced PCa. PD-L1 expression has not yet been studied regarding the androgen receptor (AR) status.</p><p><strong>Materials and methods: </strong>We investigated the effect of hormone stimulation by dihydrotestosterone (DHT) and AR inhibition by enzalutamide on PD-L1 expression in LNCaP and LNCaP-AR+ cells, the latter overexpressing AR. Cells were grown for 24 h under hormone-free conditions and then for 24 h in the presence of DHT (10 nM) and/or enzalutamide (10 μM). Cell viability was assessed by Annexin V and propidium iodi de staining. PD-L1 expression was determined semiquantitatively at the mRNA level. ANOVA and independent t-tests were used to compare experimental results between different treatment modalities.</p><p><strong>Results: </strong>DHT treatment induced some degree of apoptosis in AR-overexpressing LNCaP-AR + cells, but not in parental LNCaP cells. We found low basal expression of PD-L1 in both cell lines, with 2.7-fold higher levels in LNCaP-AR+ cells. DHT treatment increased PD-L1 expression by approximately three-fold in LNCaP cells, while in enzalutamide-treated cells, the expression was lower than the basal level. In LNCaP cells treated concomitantly with DHT and enzalutamide, AR inhibition reduced DHT-induced PD-L1, suggesting an androgen-dependent expression of PD-L1. Unlike in LNCaP cells, androgen stimulation did not increase PD-L1 expression in LNCaP-AR+ cells, and enzalutamide did not affect PD-L1 expression either.</p><p><strong>Conclusion: </strong>Our data reveal that PD-L1 is expressed in an AR-dependent manner in PCa cells, and its expression in AR-overexpressing cells is not modulated by receptor inhibition.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"47 1","pages":"60-67"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15407/exp-oncology.2025.01.060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Immune checkpoint blockade (ICB) therapy targeting the PD-1/PD-L1 axis results in poor outcomes in prostate cancer (PCa). PD-L1, the most commonly used predictive marker for the efficacy of PD-1/PD-L1-targeted immunotherapy, appears to be rarely or at low levels expressed in primary androgen-responsive PCa tumors, with higher levels in advanced PCa. PD-L1 expression has not yet been studied regarding the androgen receptor (AR) status.

Materials and methods: We investigated the effect of hormone stimulation by dihydrotestosterone (DHT) and AR inhibition by enzalutamide on PD-L1 expression in LNCaP and LNCaP-AR+ cells, the latter overexpressing AR. Cells were grown for 24 h under hormone-free conditions and then for 24 h in the presence of DHT (10 nM) and/or enzalutamide (10 μM). Cell viability was assessed by Annexin V and propidium iodi de staining. PD-L1 expression was determined semiquantitatively at the mRNA level. ANOVA and independent t-tests were used to compare experimental results between different treatment modalities.

Results: DHT treatment induced some degree of apoptosis in AR-overexpressing LNCaP-AR + cells, but not in parental LNCaP cells. We found low basal expression of PD-L1 in both cell lines, with 2.7-fold higher levels in LNCaP-AR+ cells. DHT treatment increased PD-L1 expression by approximately three-fold in LNCaP cells, while in enzalutamide-treated cells, the expression was lower than the basal level. In LNCaP cells treated concomitantly with DHT and enzalutamide, AR inhibition reduced DHT-induced PD-L1, suggesting an androgen-dependent expression of PD-L1. Unlike in LNCaP cells, androgen stimulation did not increase PD-L1 expression in LNCaP-AR+ cells, and enzalutamide did not affect PD-L1 expression either.

Conclusion: Our data reveal that PD-L1 is expressed in an AR-dependent manner in PCa cells, and its expression in AR-overexpressing cells is not modulated by receptor inhibition.

通过雄激素受体抑制前列腺癌细胞中pd-l1表达的调节取决于受体状态。
背景:针对PD-1/PD-L1轴的免疫检查点阻断(ICB)治疗导致前列腺癌(PCa)的预后不佳。PD-L1是最常用的PD-1/PD-L1靶向免疫治疗疗效的预测标志物,在原发性雄激素反应性PCa肿瘤中很少或低水平表达,在晚期PCa中表达水平较高。PD-L1在雄激素受体(AR)状态下的表达尚未被研究。材料和方法:研究了双氢睾酮(DHT)激素刺激和恩杂鲁胺(enzalutamide) AR抑制对LNCaP和LNCaP-AR+细胞PD-L1表达的影响。LNCaP-AR+细胞过表达AR,在无激素条件下培养24 h,然后在DHT (10 nM)和/或恩杂鲁胺(10 μM)存在下培养24 h。膜联蛋白V和碘丙啶染色测定细胞活力。在mRNA水平上半定量测定PD-L1的表达。采用方差分析和独立t检验比较不同治疗方式的实验结果。结果:DHT处理可诱导ar过表达的LNCaP- ar +细胞发生不同程度的凋亡,而亲代LNCaP细胞则无凋亡。我们发现两种细胞系中PD-L1的基础表达均较低,LNCaP-AR+细胞中PD-L1的基础表达水平高出2.7倍。DHT处理使LNCaP细胞中PD-L1的表达增加了约3倍,而在enzalutamide处理的细胞中,PD-L1的表达低于基础水平。在与DHT和enzalutamide同时处理的LNCaP细胞中,AR抑制降低了DHT诱导的PD-L1,提示PD-L1的雄激素依赖性表达。与LNCaP细胞不同,雄激素刺激并没有增加LNCaP- ar +细胞中PD-L1的表达,恩杂鲁胺也没有影响PD-L1的表达。结论:我们的数据显示PD-L1在PCa细胞中以ar依赖的方式表达,并且其在ar过表达细胞中的表达不受受体抑制的调节。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信